Linzagolix choline

Overview

Linzagolix choline (KLH-2109 choline) is a non-peptide gonadotropin-releasing hormone ( GnRH ) antagonist with oral activity. Linzagolix choline inhibits the release of endogenous gonadotropins such as luteinizing hormone LH and follicle-stimulating hormone FSH by binding to the GnRH receptor within the pituitary gland. This inhibition results in a reduction in the production of sex hormones such as estrogen and progesterone, which in turn affects the course of sex hormone-dependent diseases. Linzagolix choline can be used in the study of sex hormone-dependent diseases such as endometriosis and uterine fibroids.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > GnRH Receptor

Product Information

• Catalog No.: HY-120767
• CAS No.: 1321816-57-2
• Molecular Formula: C27H28F3N3O8S
• Molecular Weight: 611.59
• Purity: 99.60%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source